The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations.
BACKGROUND
A health technology assessment (HTA) of catheter ablation for atrial fibrillation (CA-AF) was commissioned by the Belgian government and performed by the Belgian Health Care Knowledge Centre (KCE). In this context, a systematic review of the economic literature was performed to assess the procedure's value for money.


METHODS
A systematic search for economic literature about the cost-effectiveness of CA-AF was performed by consulting various databases: CRD (Centre for Reviews and Dissemination) HTA and CDSR (Cochrane Database of Systematic Reviews) Technology Assessment, websites of HTA institutes, NHS EED (NHS Economic Evaluation Database), Medline (OVID), EMBASE and EconLit. No time or language restrictions were imposed and pre-defined selection criteria were used. The two-step selection procedure was performed by two persons. References of the selected studies were checked for additional relevant citations.


RESULTS
Out of 697 references, seven relevant studies were selected. Based on current evidence and economic considerations, the rationale to support catheter ablation as first-line treatment was lacking.The economic evaluations for second-line catheter ablation included several assumptions that make the results rather optimistic or subject to large uncertainty. First, overall AAD (antiarrhythmic drugs) use after ablation was higher in reality than assumed in the economic evaluations, which had its impact on costs and effects. Second, several models focused on the impact of ablation on preventing stroke. This was questionable because there was no direct hard evidence from RCTs to support this assumption. An indirect impact through stroke on mortality should also be regarded with caution. Furthermore, all models included an impact on quality of life (QoL)/utility and assumed a long-term impact. Unfortunately, none of the RCTs measured QoL with a generic utility instrument and information on the long-term impact on both mortality and QoL was lacking.


CONCLUSIONS
Catheter ablation is associated with high initial costs and may lead to life-threatening complications. Its cost-effectiveness depends on the belief one places on the impact on utility and/or preventing stroke, and the duration of these effects. Having no hard evidence for these important variables is rather troublesome. Although the technique is widely spread, the scientific evidence is insufficient for drawing conclusions about the intervention's cost-effectiveness.
Belgian Health Care Knowledge Centre (KCE), Doorbuilding Kruidtuinlaan 55, B-1000, Brussels, Belgium. mattias.neyt@kce.fgov.be.
Mattias
M
Neyt
Hans
H
Van Brabandt
Carl
C
Devos
D000889:Anti-Arrhythmia Agents / Q000191:economics / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000191:economics* / Q000453:epidemiology / Q000601:surgery*; D001530:Belgium / Q000453:epidemiology; D017115:Catheter Ablation / Q000191:economics* / Q000379:methods; D003362:Cost-Benefit Analysis / Q000379:methods; D006801:Humans
D000889:Anti-Arrhythmia Agents